Viking Therapeutics Stock
StockStockPrice
Frequently asked questions
What is Viking Therapeutics's market capitalization?
What is the Earnings Per Share (EPS) for Viking Therapeutics?
What are the analyst ratings and target price for Viking Therapeutics's stock?
What is the EBITDA for Viking Therapeutics?
What is the free cash flow of Viking Therapeutics?
What is the 5-year beta of Viking Therapeutics's stock?
How many employees does Viking Therapeutics have, and what sector and industry does it belong to?
What is the free float of Viking Therapeutics's shares?
Financials
Market Cap
$8.00B5Y beta
1.00EPS (TTM)
-$0.937Free Float
104.07MEBITDA (TTM)
-$133.97MFree Cashflow (TTM)
-$74.25MPricing
Analyst Ratings
The price target is $114.20 and the stock is covered by 11 analysts.
Buy
11
Hold
0
Sell
0
Information
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for treatment of metabolic and endocrine disorders. The Company's clinical programs include VK2809, an orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders, which is being evaluated in a Phase II b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. The Company is developing VK0214, which is also an orally available, tissue and receptor-subtype selective agonist of TRb for X-linked adrenoleukodystrophy (X-ALD), a rare X-linked, inherited neurological disorder characterized by a breakdown in the protective barriers surrounding brain and nerve cells. It is also developing VK2735, a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the treatment of various metabolic disorders.
33
Biotechnology & Drugs
Health Care
Identifier
ISIN
Primary Ticker